Systematic Review and Meta-Analysis of Bone Marrow-Derived Mononuclear Cells in Animal Models of Ischemic Stroke

Stroke

Volumn 47, Issue 6, 2016, Pages 1632-1639

  Vahidy, Farhaan S ^a   Rahbar, Mohammad H ^b   Zhu, Hongjian ^b   Rowan, Paul J ^b   Bambhroliya, Arvind B ^a   Savitz, Sean I ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

animal experimentation; bone marrow cells; mesenchymal stem cells; monocytes; stroke

Indexed keywords

ARTICLE; BONE MARROW DERIVED MONONUCLEAR CELL; BRAIN ISCHEMIA; CYLINDER TEST; EFFECT SIZE; FUNCTIONAL ASSESSMENT; HISTOLOGY; META ANALYSIS (TOPIC); NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; ANIMAL; BONE MARROW TRANSPLANTATION; DISEASE MODEL; META ANALYSIS; MONOCYTE; STROKE; TRANSPLANTATION;

ANIMALS; BONE MARROW TRANSPLANTATION; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; MONOCYTES; STROKE;

EID: 84966708263     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.116.012701     Document Type: Article

References (63)

1. Murray CJ, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D, et al; US Burden of Disease Collaborators. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA. 2013;310:591-608. doi: 10.1001/jama.2013.13805.
2. Schwamm LH, Ali SF, Reeves MJ, Smith EE, Saver JL, Messe S, et al. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals. Circ Cardiovasc Qual Outcomes. 2013;6:543-549. doi: 10.1161/CIRCOUTCOMES.111.000303.
3. Grotta JC, Hacke W. Stroke neurologist's perspective on the new endovascular trials. Stroke. 2015;46:1447-1452. doi: 10.1161/STROKEAHA.115.008384.
4. Savitz SI. Developing cellular therapies for stroke. Stroke. 2015;46:2026-2031. doi: 10.1161/STROKEAHA.115.007149.
5. Iihoshi S, Honmou O, Houkin K, Hashi K, Kocsis JD. A therapeutic window for intravenous administration of autologous bone marrow after cerebral ischemia in adult rats. Brain Res. 2004;1007:1-9. doi: 10.1016/j.brainres.2003.09.084.
6. Kamiya N, Ueda M, Igarashi H, Nishiyama Y, Suda S, Inaba T, et al. Intra-arterial transplantation of bone marrow mononuclear cells immediately after reperfusion decreases brain injury after focal ischemia in rats. Life Sci. 2008;83:433-437. doi: 10.1016/j.lfs.2008.07.018.
7. Giraldi-Guimardes A, Rezende-Lima M, Bruno FP, Mendez-Otero R. Treatment with bone marrow mononuclear cells induces functional recovery and decreases neurodegeneration after sensorimotor cortical ischemia in rats. Brain Res. 2009;1266:108-120. doi: 10.1016/j. brainres.2009.01.062.
8. Brenneman M, Sharma S, Harting M, Strong R, Cox CS Jr, Aronowski J, et al. Autologous bone marrow mononuclear cells enhance recovery after acute ischemic stroke in young and middle-aged rats. J Cereb Blood Flow Metab. 2010;30:140-149. doi: 10.1038/jcbfm.2009.198.
9. Kamiya F, Ueda M, Nito C, Kamiya N, Inaba T, Suda S, et al. Effect of repeated allogeneic bone marrow mononuclear cell transplantation on brain injury following transient focal cerebral ischemia in rats. Life Sci. 2014;95:22-28. doi: 10.1016/j.lfs.2013.12.016.
10. Prabhakar S, Muthaian R, Chabbra R, Anand A. Analysis of homing potential of marrow-derived mononuclear cells in an experimentallyinduced brain stroke mouse model. Brain Inj. 2010;24:1485-1490. doi: 10.3109/02699052.2010.520298.
11. Fujita Y, Ihara M, Ushiki T, Hirai H, Kizaka-Kondoh S, Hiraoka M, et al. Early protective effect of bone marrow mononuclear cells against ischemic white matter damage through augmentation of cerebral blood flow. Stroke. 2010;41:2938-2943. doi: 10.1161/STROKEAHA.110.596379.
12. Sharma S, Yang B, Strong R, Xi X, Brenneman M, Grotta JC, et al. Bone marrow mononuclear cells protect neurons and modulate microglia in cell culture models of ischemic stroke. J Neurosci Res. 2010;88:2869-2876. doi: 10.1002/jnr.22452.
13. Nakano-Doi A, Nakagomi T, Fujikawa M, Nakagomi N, Kubo S, Lu S, et al. Bone marrow mononuclear cells promote proliferation of endogenous neural stem cells through vascular niches after cerebral infarction. Stem Cells. 2010;28:1292-1302. doi: 10.1002/stem.454.
14. Wang J, Yu L, Jiang C, Chen M, Ou C, Wang J. Bone marrow mononuclear cells exert long-term neuroprotection in a rat model of ischemic stroke by promoting arteriogenesis and angiogenesis. Brain Behav Immun. 2013;34:56-66. doi: 10.1016/j.bbi.2013.07.010.
15. Wang J, Fu X, Jiang C, Yu L, Wang M, Han W, et al. Bone marrow mononuclear cell transplantation promotes therapeutic angiogenesis via upregulation of the VEGF-VEGFR2 signaling pathway in a rat model of vascular dementia. Behav Brain Res. 2014;265:171-180. doi: 10.1016/j. bbr.2014.02.033.
16. Yang B, Xi X, Aronowski J, Savitz SI. Ischemic stroke may activate bone marrow mononuclear cells to enhance recovery after stroke. Stem Cells Dev. 2012;21:3332-3340. doi: 10.1089/scd.2012.0037.
17. Savitz SI, Misra V, Kasam M, Juneja H, Cox CS Jr, Alderman S, et al. Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol. 2011;70:59-69. doi: 10.1002/ana.22458.
18. Mendonça ML, Freitas GR, Silva SA, Manfrim A, Falcão CH, Gonzáles C, et al. [Safety of intra-arterial autologous bone marrow mononuclear cell transplantation for acute ischemic stroke]. Arq Bras Cardiol. 2006;86:52-55. doi: /S0066-782X2006000100008.
19. Correa PL, Mesquita CT, Felix RM, Azevedo JC, Barbirato GB, Falcão CH, et al. Assessment of intra-arterial injected autologous bone marrow mononuclear cell distribution by radioactive labeling in acute ischemic stroke. Clin Nucl Med. 2007;32:839-841. doi: 10.1097/RLU.0b013e318156b980.
20. Barbosa da Fonseca LM, Battistella V, de Freitas GR, Gutfilen B, Dos Santos Goldenberg RC, Maiolino A, et al. Early tissue distribution of bone marrow mononuclear cells after intra-arterial delivery in a patient with chronic stroke. Circulation. 2009;120:539-541. doi: 10.1161/CIRCULATIONAHA.109.863084.
21. Barbosa da Fonseca LM, Gutfilen B, Rosado de Castro PH, Battistella V, Goldenberg RC, Kasai-Brunswick T, et al. Migration and homing of bone-marrow mononuclear cells in chronic ischemic stroke after intra-arterial injection. Exp Neurol. 2010;221:122-128. doi: 10.1016/j. expneurol.2009.10.010.
22. Battistella V, de Freitas GR, da Fonseca LM, Mercante D, Gutfilen B, Goldenberg RC, et al. Safety of autologous bone marrow mononuclear cell transplantation in patients with nonacute ischemic stroke. Regen Med. 2011;6:45-52. doi: 10.2217/rme.10.97.
23. Friedrich MA, Martins MP, Araújo MD, Klamt C, Vedolin L, Garicochea B, et al. Intra-arterial infusion of autologous bone marrow mononuclear cells in patients with moderate to severe middle cerebral artery acute ischemic stroke. Cell Transplant. 2012;21(suppl 1):S13-S21. doi: 10.3727/096368911X612512.
24. Prasad K, Mohanty S, Bhatia R, Srivastava MV, Garg A, Srivastava A, et al. Autologous intravenous bone marrow mononuclear cell therapy for patients with subacute ischaemic stroke: a pilot study. Indian J Med Res. 2012;136:221-228.
25. Moniche F, Gonzalez A, Gonzalez-Marcos JR, Carmona M, Piñero P, Espigado I, et al. Intra-arterial bone marrow mononuclear cells in ischemic stroke: a pilot clinical trial. Stroke. 2012;43:2242-2244. doi: 10.1161/STROKEAHA.112.659409.
26. Bhasin A, Srivastava MV, Mohanty S, Bhatia R, Kumaran SS, Bose S. Stem cell therapy: a clinical trial of stroke. Clin Neurol Neurosurg. 2013;115:1003-1008. doi: 10.1016/j.clineuro.2012.10.015.
27. Rosado-de-Castro PH, Schmidt Fda R, Battistella V, Lopes de Souza SA, Gutfilen B, Goldenberg RC, et al. Biodistribution of bone marrow mononuclear cells after intra-arterial or intravenous transplantation in subacute stroke patients. Regen Med. 2013;8:145-155.
28. Sharma A, Sane H, Nagrajan A, Gokulchandran N, Badhe P, Paranjape A, et al. Autologous bone marrow mononuclear cells in ischemic cerebrovascular accident paves way for neurorestoration: a case report. Case Rep Med. 2014;2014:530239. doi: 10.1155/2014/530239.
29. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-269. doi: 10.7326/0003-4819-151-4-200908180-00135.
30. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, et al; STAIR Group. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40:2244-2250. doi: 10.1161/STROKEAHA.108.541128.
31. Durlak JA. How to select, calculate, and interpret effect sizes. J Pediatr Psychol. 2009;34:917-928. doi: 10.1093/jpepsy/jsp004.
32. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558. doi: 10.1002/sim.1186.
33. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.
34. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
35. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323:101-105.
36. Rosenthal R. The file drawer problem and tolerance for null results. Psychol Bull. 1979;86:638-641.
37. Orwin RG. A fail-safe n for effect size in meta-analysis. J Educ Stat. 1983;8:157-159. doi: 10.2307/1164923.
38. de Vasconcelos Dos Santos A, da Costa Reis J, Diaz Paredes B, Moraes L, Jasmin, Giraldi-Guimarães A, et al. Therapeutic window for treatment of cortical ischemia with bone marrow-derived cells in rats. Brain Res. 2010;1306:149-158. doi: 10.1016/j.brainres.2009.09.094.
39. Taguchi A, Zhu P, Cao F, Kikuchi-Taura A, Kasahara Y, Stern DM, et al. Reduced ischemic brain injury by partial rejuvenation of bone marrow cells in aged rats. J Cereb Blood Flow Metab. 2011;31:855-867. doi: 10.1038/jcbfm.2010.165.
40. Yang B, Strong R, Sharma S, Brenneman M, Mallikarjunarao K, Xi X, et al. Therapeutic time window and dose response of autologous bone marrow mononuclear cells for ischemic stroke. J Neurosci Res. 2011;89:833-839. doi: 10.1002/jnr.22614.
41. Zhang XM, Du F, Yang D, Wang R, Yu CJ, Huang XN, et al. Granulocyte colony-stimulating factor increases the therapeutic efficacy of bone marrow mononuclear cell transplantation in cerebral ischemia in mice. BMC Neurosci. 2011;12:61. doi: 10.1186/1471-2202-12-61.
42. de Freitas HT, da Silva VG, Giraldi-Guimarães A. Comparative study between bone marrow mononuclear fraction and mesenchymal stem cells treatment in sensorimotor recovery after focal cortical ablation in rats. Behav Brain Funct. 2012;8:58. doi: 10.1186/1744-9081-8-58.
43. Franco EC, Cardoso MM, Gouvêia A, Pereira A, Gomes-Leal W. Modulation of microglial activation enhances neuroprotection and functional recovery derived from bone marrow mononuclear cell transplantation after cortical ischemia. Neurosci Res. 2012;73:122-132. doi: 10.1016/j.neures.2012.03.006.
44. Kasam M, Yang B, Strong R, Schaar K, Misra V, Xi X, et al. Nitric oxide facilitates delivery and mediates improved outcome of autologous bone marrow mononuclear cells in a rodent stroke model. PLoS One. 2012;7:e32793. doi: 10.1371/journal.pone.0032793.
45. Vasconcelos-dos-Santos A, Rosado-de-Castro PH, Lopes de Souza SA, da Costa Silva J, Ramos AB, Rodriguez de Freitas G, et al. Intravenous and intra-arterial administration of bone marrow mononuclear cells after focal cerebral ischemia: is there a difference in biodistribution and efficacy? Stem Cell Res. 2012;9:1-8. doi: 10.1016/j.scr.2012.02.002.
46. Wagner DC, Bojko M, Peters M, Lorenz M, Voigt C, Kaminski A, et al. Impact of age on the efficacy of bone marrow mononuclear cell transplantation in experimental stroke. Exp Transl Stroke Med. 2012;4:17. doi: 10.1186/2040-7378-4-17.
47. Cardoso MM, Franco EC, de Souza CC, da Silva MC, Gouveia A, Gomes-Leal W. Minocycline treatment and bone marrow mononuclear cell transplantation after endothelin-1 induced striatal ischemia. Inflammation. 2013;36:197-205. doi: 10.1007/s10753-012-9535-5.
48. dos Santos Sampaio MdF, dos Santos Marcilio F, Giraldi-Guimarães A. Does treatment with bone marrow mononuclear cells recover skilled motor function after focal cortical ischemia? Analysis with a forelimb skilled motor task in rats. Brain Res. 2013;1492:130-139. doi: 10.1016/j. brainres.2012.11.026.
49. Jiang C, Wang J, Yu L, Ou C, Liu X, Zhao X, et al. Comparison of the therapeutic effects of bone marrow mononuclear cells and microglia for permanent cerebral ischemia. Behav Brain Res. 2013;250:222-229. doi: 10.1016/j.bbr.2013.05.011.
50. Yang B, Migliati E, Parsha K, Schaar K, Xi X, Aronowski J, et al. Intra-arterial delivery is not superior to intravenous delivery of autologous bone marrow mononuclear cells in acute ischemic stroke. Stroke. 2013;44:3463-3472. doi: 10.1161/STROKEAHA.111.000821.
51. Coelho BP, Giraldi-Guimarães A. Effect of age and gender on recovery after stroke in rats treated with bone marrow mononuclear cells. Neurosci Res. 2014;88:67-73. doi: 10.1016/j.neures.2014.08.007.
52. Minnerup J, Wagner DC, Strecker JK, Pösel C, Sevimli-Abdis S, Schmidt A, et al. Bone marrow-derived mononuclear cells do not exert acute neuroprotection after stroke in spontaneously hypertensive rats. Front Cell Neurosci. 2014;7:288. doi: 10.3389/fncel.2013.00288.
53. Suda S, Katsura KI, Saito M, Kamiya N, Katayama Y. Valproic acid enhances the effect of bone marrow-derived mononuclear cells in a rat ischemic stroke model. Brain Res. 2014;1565:74-81. doi: 10.1016/j. brainres.2014.04.011.
54. Janowski M, Walczak P, Date I. Intravenous route of cell delivery for treatment of neurological disorders: a meta-analysis of preclinical results. Stem Cells Dev. 2010;19:5-16. doi: 10.1089/scd.2009.0271.
55. Lees JS, Sena ES, Egan KJ, Antonic A, Koblar SA, Howells DW, et al. Stem cell-based therapy for experimental stroke: a systematic review and meta-analysis. Int J Stroke. 2012;7:582-588. doi: 10.1111/j.1747-4949.2012.00797.x.
56. Vu Q, Xie K, Eckert M, Zhao W, Cramer SC. Meta-analysis of preclinical studies of mesenchymal stromal cells for ischemic stroke. Neurology. 2014;82:1277-1286. doi: 10.1212/WNL.0000000000000278.
57. Dharmasaroja P. Bone marrow-derived mesenchymal stem cells for the treatment of ischemic stroke. J Clin Neurosci. 2009;16:12-20. doi: 10.1016/j.jocn.2008.05.006.
58. Schaar KL, Brenneman MM, Savitz SI. Functional assessments in the rodent stroke model. Exp Transl Stroke Med. 2010;2:13. doi: 10.1186/2040-7378-2-13.
59. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408-412.
60. Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 2013;14:365-376. doi: 10.1038/nrn3475.
61. Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet. 2002;359:614-618. doi: 10.1016/S0140-6736(02)07750-4.
62. Mergenthaler P, Meisel A. Do stroke models model stroke? Dis Model Mech. 2012;5:718-725. doi: 10.1242/dmm.010033.
63. Sena ES, Briscoe CL, Howells DW, Donnan GA, Sandercock PA, Macleod MR. Factors affecting the apparent efficacy and safety of tissue plasminogen activator in thrombotic occlusion models of stroke: systematic review and meta-analysis. J Cereb Blood Flow Metab. 2010;30:1905-1913. doi: 10.1038/jcbfm.2010.116.